Corporate & Investor Presentation

Track record of strong financial returns for shareholders $1.8 Revenue ($B) 12% CAGR $3.1 LTM 3Q16 LTM 3Q21 Non-GAAP Operating Income ($M) 17% CAGR $442 $977 LTM 3Q16 LTM 3Q21 Non-GAAP EPS 15% CAGR $5.31 $2.69 LTM 3Q16 LTM 3Q21 Total shareholder return, TSR (NYSE shares as of 3/31/2021): 1-yr 32% | 3-yr 104% | 5-yr 261% NOTE: See reconciliation to GAAP in Appendix 31 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed

View entire presentation